Sphera Funds Management’s Structure Therapeutics GPCR Stock Holding History

Sphera Funds Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.45M	Buy	50,800 +9,800	+24%	+$671K	0.39%	73
2025 Q4	$2.85M	Sell	41,000 -132,931	-76%	-$5.43M	0.55%	65
2025 Q3	$4.87M	Buy	173,931 +78,000	+81%	+$1.55M	1.03%	33
2025 Q2	$1.99M	Buy	95,931 +11,931	+14%	+$262K	0.47%	69
2025 Q1	$1.45M	Buy	+84,000	New	+$2.06M	0.33%	77

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Sphera Funds Management's GPCR Position: Q1 2026 in Review

Sphera Funds Management increased its Structure Therapeutics (GPCR) stake by 24% in Q1 2026, buying an estimated $671K and bringing the position to 50,800 shares worth $2.45M. The position accounts for 0.39% of the portfolio, ranked #73.

Sphera Funds Management first reported a position in GPCR in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.87M in Q3 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Sphera Funds Management held 50,800 shares of Structure Therapeutics worth $2.45M as of Q1 2026.
Sphera Funds Management bought 9,800 Structure Therapeutics shares in Q1 2026, an estimated $671K.
Structure Therapeutics made up 0.39% of Sphera Funds Management's portfolio in Q1 2026, its #73 holding.
Sphera Funds Management first reported a position in Structure Therapeutics in Q1 2025 and has held it in 5 quarters since.
Sphera Funds Management's Structure Therapeutics position peaked at $4.87M in Q3 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.